Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.34 |
| ▸ | ITGAV | P06756 | 9/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241452 | 0.84 | KCNE1 (0.37) | KCNE1KCNA5KCNQ1KCND3ITGB3 | |
| SCHEMBL1242211 | 0.81 | KCNA5 (0.33) | KCNE1KCNA5KCNQ1KCND3SMN1; SMN2 | |
| SCHEMBL1243091 | 0.78 | KCNA5 (0.40) | KCNE1KCNA5KCND3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1243310 | 0.78 | KCNA5 (0.40) | KCNE1KCNA5KCND3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1241967 | 0.78 | KCNA5 (0.40) | KCNE1KCNA5KCND3ALDH1A1SMN1; SMN2 | |
| SCHEMBL4196212 | 0.78 | CYP3A4 (0.48) | KCNA5ALDH1A1CYP2C9SMN1; SMN2 | |
| SCHEMBL1242156 | 0.77 | CFTR (0.42) | KCNA5SMN1; SMN2 | |
| SCHEMBL1242437 | 0.72 | KCNA5 (0.42) | KCNE1KCNA5KCNQ1KCND3 | |
| SCHEMBL3885685 | 0.71 | KCNA5 (0.51) | KCNE1KCNA5KCNQ1KCND3MAP3K5 | |
| SCHEMBL1383486 | 0.70 | TSHR (0.51) | KCNE1KCNA5KCNQ1KCND3MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNE1 23/4885KCNA5 11/4885KCNQ1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.